Elite Journal of Laboratory Medicine. Volume 2 Issue 6(2024), Pp. 10-23
https://epjournals.com/journals/EJLM

# Optimizing Transfusion Practices for Maternal-Fetal Well-being: Challenges and Innovations

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

## Abstract

Transfusion practices in obstetrics are critical for managing maternal complications such as postpartum hemorrhage and severe anemia, which can significantly impact maternal and fetal health. This review explores the challenges encountered in obstetric transfusion and discusses innovative approaches aimed at optimizing maternal-fetal well-being. Effective management of obstetric transfusion begins with understanding the unique physiological changes and clinical indications specific to pregnancy. Physiological adaptations during pregnancy, including alterations in blood volume and hemodynamics, necessitate tailored transfusion strategies to mitigate risks and optimize outcomes for both mother and fetus. Clear guidelines and evidence-based transfusion triggers are crucial for guiding clinical decision-making and ensuring timely interventions, particularly in emergent obstetric scenarios. Safety remains paramount in obstetric transfusion, with risks including transfusion reactions, infectious complications, and immunological responses. Advances in transfusion medicine, such as leukoreduction and pathogen reduction technologies, contribute to enhancing the safety profile of blood products. Innovations in blood product management, including extended storage techniques and cryopreservation, support rapid access and availability during critical obstetric emergencies.

***Keywords****: transfusion practices, maternal-fetal health, challenges, innovations*

## Introduction

Transfusion practices in obstetrics play a pivotal role in managing critical conditions that threaten maternal and fetal health, such as postpartum hemorrhage (PPH) and severe maternal anemia. These conditions remain significant contributors to maternal mortality globally, highlighting the crucial need for effective transfusion strategies. Obstetric transfusion differs from general transfusion practices due to the unique physiological changes of pregnancy, the urgency of obstetric emergencies, and the dual consideration of maternal and fetal outcomes. The optimization

of transfusion practices in this context involves navigating complex clinical scenarios, ethical considerations, technological advancements, and evolving evidence-based guidelines.[1-5] Maternal hemorrhage, particularly PPH, remains a leading cause of maternal mortality worldwide. Defined as excessive bleeding within 24 hours of childbirth, PPH requires prompt intervention to stabilize maternal hemodynamics and prevent life-threatening complications. Transfusion of blood products, including packed red blood cells (PRBCs), plasma, and platelets, is often essential in managing PPH, restoring blood volume and coagulation factors to mitigate the risk of hemorrhagic shock. Effective transfusion strategies not only save lives but also contribute to reducing maternal morbidity and long-term health complications associated with severe blood loss during childbirth.[6-10]

Severe maternal anemia poses another significant challenge in obstetric care, affecting maternal health and fetal development. Anemia in pregnancy is commonly defined by hemoglobin levels below 11 g/dL, with severe cases (<7-8 g/dL) requiring transfusion to improve oxygen delivery to maternal tissues and across the placenta. Transfusion therapy aims to alleviate symptoms of anemia, such as fatigue and cardiovascular strain, while minimizing risks of adverse outcomes such as preterm birth and intrauterine growth restriction (IUGR). Optimizing transfusion practices involves balancing the benefits of correcting maternal anemia with the potential risks associated with transfusion-related complications, underscoring the importance of individualized care approaches guided by clinical indications and evidence-based protocols.[11-15] Innovations such as leukoreduction, which removes white blood cells to reduce transfusion reactions, and pathogen reduction technologies, which enhance blood safety by inactivating pathogens, have significantly improved the safety profile of blood products. These advancements are complemented by the development of rapid point-of-care testing devices that facilitate timely assessment of maternal hemodynamics, coagulation parameters, and blood compatibility, enabling healthcare providers to initiate appropriate transfusion therapy promptly.[16-20] Ethical considerations in obstetric transfusion encompass patient autonomy, informed consent, and cultural preferences, particularly regarding blood transfusions. Pregnant women may face dilemmas in balancing religious beliefs or personal preferences with medical recommendations for transfusion therapy. Healthcare providers must engage in sensitive discussions, provide comprehensive information about transfusion risks and benefits, and respect patient choices while prioritizing maternal and fetal well-being. Addressing these ethical dimensions is essential for ensuring patient-centered care and promoting trust between healthcare providers and pregnant women.[21-25] Optimizing transfusion practices in obstetrics also entails addressing healthcare disparities, ensuring equitable access to transfusion services, and enhancing healthcare infrastructure in underserved regions. Collaborative efforts among healthcare providers, transfusion specialists, policymakers, and international organizations are crucial in developing sustainable transfusion programs, promoting blood donation campaigns, and improving transfusion readiness in emergencies. By fostering global partnerships and advocating for transfusion safety standards, healthcare systems can enhance maternal-fetal outcomes and reduce preventable maternal deaths worldwide.[26-30]

**Physiological Considerations**

Transfusion practices in obstetrics must carefully consider the unique physiological changes that occur during pregnancy, influencing both maternal and fetal responses to transfusion therapy.

**1. Maternal Hemodynamics:** Pregnancy induces significant changes in maternal hemodynamics to support fetal growth and development. Plasma volume increases by approximately 40-50%, leading to hemodilution and a physiological decrease in hemoglobin concentration. This adaptation ensures adequate oxygen delivery to maternal tissues and the placenta. However, these hemodynamic changes alter the threshold for diagnosing anemia in pregnancy and influence transfusion triggers. Healthcare providers must carefully monitor maternal hemodynamics during transfusion therapy to avoid volume overload or exacerbation of pre-existing cardiovascular conditions.[31-32]

**2. Oxygen Delivery and Fetal Considerations:** Transfusion therapy aims to improve oxygen delivery to maternal tissues and, consequently, across the placenta to the fetus. Severe maternal anemia compromises oxygenation, potentially affecting fetal growth and development. Transfusing packed red blood cells (PRBCs) restores oxygen-carrying capacity, alleviating maternal symptoms and enhancing fetal oxygenation. However, balancing maternal benefits with fetal risks, such as hyperbilirubinemia or alloimmunization, requires careful consideration. Monitoring fetal well-being through ultrasound and fetal heart rate monitoring during and after transfusion helps mitigate these risks.[33-35]

**3. Immunological Considerations:** Immunological factors play a crucial role in obstetric transfusion, particularly regarding blood group compatibility and Rh sensitization. Rh-negative mothers require Rh immune globulin (RhIg) prophylaxis to prevent alloimmunization if exposed to Rh-positive fetal blood during pregnancy or childbirth. Transfusion-related immunomodulation may also impact maternal immune responses, potentially affecting maternal-fetal tolerance and immune-mediated complications. Understanding these immunological dynamics ensures appropriate blood product selection and transfusion management to minimize risks and optimize maternal and fetal outcomes.[36-38]

**4. Coagulation Changes and Hemostasis:** Pregnancy is associated with complex changes in coagulation and fibrinolytic pathways to mitigate hemorrhagic risks during childbirth. Physiological hypercoagulability increases thrombotic tendencies, whereas labor and delivery can lead to temporary coagulation factor consumption and increased bleeding tendencies postpartum. Transfusion of fresh frozen plasma (FFP) or specific clotting factors may be necessary to correct coagulopathies and manage obstetric hemorrhage effectively. Monitoring coagulation profiles and adjusting transfusion therapy accordingly are critical in maintaining hemostatic balance and preventing adverse outcomes.[39-41]

**5. Renal and Hepatic Adaptations:** Renal and hepatic adaptations in pregnancy influence drug metabolism, clearance, and fluid dynamics, affecting transfusion management. Impaired renal function, particularly in conditions like preeclampsia, necessitates cautious fluid management during transfusion to prevent fluid overload and exacerbate maternal hypertension. Hepatic changes alter protein synthesis and clearance rates, impacting the metabolism of coagulation

factors and plasma proteins essential for hemostasis. Transfusion strategies must consider these physiological adaptations to optimize therapeutic efficacy and minimize risks in obstetric patients.[42-44]

**Indications and Guidelines**

Transfusion therapy in obstetrics is guided by specific indications aimed at addressing critical conditions such as severe maternal anemia, postpartum hemorrhage (PPH), and other obstetric emergencies. Clear guidelines help healthcare providers make informed decisions regarding transfusion initiation, selection of blood products, and monitoring strategies to optimize maternal and fetal outcomes.

**1. Postpartum Hemorrhage (PPH):** Postpartum hemorrhage, defined as excessive bleeding within 24 hours of childbirth, remains a leading cause of maternal mortality worldwide. Transfusion is indicated when PPH is severe or refractory to initial management with uterotonics. Initial assessment includes estimating blood loss and monitoring vital signs to guide transfusion triggers. Indications for transfusion in PPH include hemodynamic instability, persistent bleeding despite uterotonics, and significant drops in hemoglobin levels necessitating correction to prevent shock and organ dysfunction.[45-46]

**2. Severe Maternal Anemia:** Severe maternal anemia in pregnancy, typically defined as hemoglobin levels less than 7-8 g/dL, warrants transfusion to improve oxygen delivery to maternal tissues and the placenta. Indications for transfusion in severe anemia include symptomatic hypoxia, cardiovascular compromise, and inadequate response to oral or intravenous iron supplementation. Transfusion therapy aims to alleviate maternal symptoms, reduce risks of adverse fetal outcomes such as preterm birth or intrauterine growth restriction (IUGR), and optimize maternal-fetal well-being.[47-48]

**3. Acute Blood Loss During Cesarean Section:** Cesarean section is associated with increased risk of hemorrhage due to surgical trauma and placental complications. Transfusion may be indicated in cases of acute blood loss during cesarean delivery to maintain hemodynamic stability and prevent hypovolemic shock. Monitoring blood loss and assessing maternal hemodynamics guide transfusion decisions, ensuring timely intervention with blood products such as PRBCs and clotting factors as needed.[49]

**4. Complications Requiring Surgical Intervention:** Obstetric complications necessitating surgical intervention, such as uterine rupture, placental abruption, or severe perineal trauma, may lead to significant blood loss requiring transfusion. Indications for transfusion in these scenarios include intraoperative hemorrhage compromising maternal hemodynamics or coagulopathies requiring correction to facilitate surgical repair and prevent further complications. Timely access to blood products and collaborative management with surgical teams are crucial in optimizing maternal outcomes.[50-51]

**5. Evidence-Based Guidelines and Transfusion Triggers:** Evidence-based guidelines provide standardized criteria for initiating transfusion therapy in obstetrics, promoting consistent and safe practices across healthcare settings. Transfusion triggers, such as hemoglobin thresholds (<7-8 g/dL in severe anemia or <6-7 g/dL in acute bleeding) or clinical indicators of hemodynamic instability, guide transfusion decisions. Guidelines also emphasize pre-transfusion testing, including blood typing, cross-matching, and assessing coagulation profiles, to ensure compatibility and minimize risks of transfusion reactions.[52-53]

**6. Monitoring and Follow-Up:** Continuous monitoring of maternal vital signs, hemoglobin levels, and clinical response to transfusion is essential in obstetric care. Serial assessments during and after transfusion help evaluate efficacy, detect adverse reactions promptly, and adjust transfusion therapy as needed. Follow-up care includes monitoring for potential complications such as fluid overload, transfusion-related infections, or alloimmunization, particularly in Rh-negative mothers requiring Rh immune globulin prophylaxis.[54-56]

**Safety Profiles and Transfusion Risks**

Transfusion therapy in obstetrics, while essential for managing critical conditions like postpartum hemorrhage and severe maternal anemia, carries inherent risks that must be carefully managed to ensure maternal and fetal safety.

**1. Transfusion Reactions:** Transfusion reactions encompass a spectrum of immune and non-immune responses to transfused blood products. Immune-mediated reactions, such as hemolytic transfusion reactions (HTRs) and febrile non-hemolytic reactions (FNHTRs), result from antigen-antibody interactions or cytokine release, respectively. Non-immune reactions include transfusion-associated circulatory overload (TACO), anaphylaxis, and transfusion-related acute lung injury (TRALI). Early recognition of symptoms, such as fever, chills, dyspnea, or hypotension, is essential for prompt intervention and management to mitigate adverse outcomes.[57-58]

**2. Infectious Complications:** Infectious risks associated with transfusion include bacterial, viral, and protozoal infections transmitted through contaminated blood products. Despite stringent donor screening and testing protocols, residual risks of transfusion-transmitted infections (TTIs) remain, albeit extremely low in developed countries. Bacterial contamination can lead to sepsis, particularly in platelet concentrates, necessitating vigilance in aseptic handling and timely administration of blood products. Emerging pathogens and evolving epidemiological trends require ongoing surveillance and adherence to blood safety protocols to minimize infectious risks.[59-60]

**3. Immunological Considerations:** Immunological responses to transfusion include alloimmunization, where recipients develop antibodies against donor antigens, particularly relevant in Rh-negative individuals exposed to Rh-positive blood. Rh immune globulin (RhIg) prophylaxis is administered to Rh-negative mothers during and after pregnancy to prevent alloimmunization and subsequent hemolytic disease of the fetus and newborn (HDFN). Monitoring maternal antibody status and selecting compatible blood products through cross-

matching procedures are essential in mitigating immunological risks and ensuring transfusion compatibility.[61]

**4. Transfusion-Related Iron Overload:** Repeated transfusions in obstetrics, particularly in patients with chronic anemia or frequent transfusion requirements, can lead to iron overload over time. Excess iron deposition in organs, such as the liver, heart, and endocrine glands, may result in organ dysfunction and long-term health complications. Monitoring iron levels and instituting iron chelation therapy as needed are critical in managing transfusion-related iron overload, minimizing associated morbidity, and optimizing patient outcomes.[62]

**5. Hemolytic Disease of the Newborn (HDN):** Maternal-fetal transfusion-related complications may include HDN, a condition where maternal antibodies cross the placenta and attack fetal red blood cells, leading to hemolysis and fetal anemia. Rh incompatibility is a primary cause, necessitating RhIg prophylaxis and careful monitoring of fetal hemoglobin levels during pregnancy and postpartum. Effective management of HDN involves specialized neonatal care, including intrauterine transfusions and close fetal monitoring to prevent severe fetal anemia and optimize neonatal outcomes.[63]

**6. Thrombotic Complications:** While pregnancy itself increases the risk of thrombotic events due to hypercoagulability, transfusion-related factors such as blood product composition and administration techniques can further contribute to thrombotic complications. Thromboembolic events, such as deep vein thrombosis (DVT) or pulmonary embolism (PE), are potential risks associated with transfusion therapy, particularly in patients with pre-existing coagulopathies or prolonged immobility. Prophylactic measures, including early mobilization and anticoagulant therapy as appropriate, help mitigate thrombotic risks in obstetric patients receiving transfusions.[64]

## Advancements in Blood Product Management

Advancements in blood product management have revolutionized obstetric transfusion practices, enhancing safety, availability, and efficacy of blood components critical for managing maternal complications such as postpartum hemorrhage and severe anemia. These advancements encompass innovations in blood collection, processing, storage, and administration techniques, aimed at optimizing maternal-fetal well-being and improving clinical outcomes in obstetric care.

**1. Leukoreduction:** One significant advancement in blood product management is leukoreduction, which involves removing white blood cells from blood components such as packed red blood cells (PRBCs) and platelets. Leukoreduction reduces the risk of febrile non-hemolytic transfusion reactions (FNHTRs), alloimmunization, and transmission of cytomegalovirus (CMV), particularly beneficial in obstetric patients vulnerable to immune-mediated complications. This process enhances the safety profile of transfused blood products, minimizing inflammatory responses and improving overall transfusion outcomes in obstetrics.[65]

**2. Pathogen Reduction Technologies:** Pathogen reduction technologies (PRTs) have been developed to further enhance blood safety by inactivating pathogens, including viruses, bacteria, and parasites, without compromising blood product quality. These technologies utilize photochemical treatments or nucleic acid targeting approaches to reduce the infectious risk associated with transfusion-transmitted infections (TTIs), such as HIV, hepatitis B and C, and Zika virus. PRTs are particularly valuable in obstetric settings where stringent infection control measures are critical to safeguard maternal and fetal health during transfusion therapy.[66]

**3. Extended Storage and Shelf-Life:** Advancements in blood product storage techniques have extended the shelf-life of blood components, improving their availability and logistical management in obstetric emergencies. Innovations in additive solutions and cryopreservation methods enable prolonged storage of plasma and platelets, ensuring readiness for immediate use in critical situations such as massive obstetric hemorrhage. Extended shelf-life enhances transfusion accessibility, reduces wastage, and supports timely administration of blood products essential for stabilizing maternal hemodynamics and preventing complications associated with acute blood loss.[67]

**4. Irradiation and Pathogen Inactivation:** Irradiation of blood products is essential for preventing transfusion-associated graft-versus-host disease (TA-GVHD), a rare but severe complication in immunocompromised obstetric patients and those receiving blood from close relatives. Irradiation disrupts donor lymphocyte function while maintaining blood product integrity, ensuring safe transfusion practices in high-risk populations. Additionally, pathogen inactivation techniques, such as amotosalen/UVA treatment for plasma and riboflavin/UV light treatment for platelets, provide an additional layer of safety by targeting pathogens' nucleic acids, further reducing the risk of TTIs in obstetric transfusion recipients.[68]

**5. Point-of-Care Testing (POCT):** Point-of-care testing (POCT) devices have revolutionized transfusion management by enabling rapid assessment of coagulation profiles, blood typing, and compatibility testing at the bedside. In obstetric emergencies, POCT facilitates immediate decision-making regarding transfusion therapy, ensuring timely administration of compatible blood products based on real-time clinical data. POCT devices enhance transfusion safety, reduce turnaround times for critical results, and optimize resource utilization in obstetric settings where rapid interventions are crucial for maternal and fetal outcomes.[69]

**6. Quality Assurance and Regulatory Standards:** Advancements in blood product management also encompass robust quality assurance (QA) programs and adherence to stringent regulatory standards to ensure product safety and efficacy. Blood establishments follow Good Manufacturing Practices (GMP) and regulatory guidelines set forth by health authorities to maintain high standards of blood collection, processing, storage, and distribution. Continuous monitoring of transfusion-related adverse events, hemovigilance programs, and ongoing research contribute to refining transfusion practices and improving patient outcomes in obstetric care.[70]

**Optimizing Transfusion Practices**

Transfusion therapy plays a pivotal role in the treatment of patients across diverse medical specialties, ranging from critical care and surgery to oncology and obstetrics. The optimization of transfusion practices involves a careful balance between meeting patient-specific needs and minimizing potential risks associated with transfusion-related complications.

**Challenges in Transfusion Practices**

1. **Blood Product Availability and Logistics**: One of the primary challenges in transfusion medicine is ensuring an adequate supply of blood products while maintaining their quality and safety. Variability in demand, shelf-life considerations, and the logistical complexities of storage and transportation pose significant challenges, especially in regions with limited resources or during emergencies.
2. **Transfusion-related Complications**: While transfusions are life-saving interventions, they are not without risks. Complications such as transfusion reactions, infections, and immunological responses necessitate stringent protocols for donor screening, blood testing, and compatibility matching to minimize adverse events.
3. **Cost and Resource Utilization**: The economic burden of transfusion therapy includes the costs associated with blood procurement, testing, administration, and management of transfusion-related complications. Optimizing resource utilization while maintaining high-quality patient care is essential for sustainable transfusion practices.
4. **Patient Blood Management**: Promoting patient blood management (PBM) strategies involves a multidisciplinary approach to optimize transfusion decisions, reduce unnecessary transfusions, and conserve blood resources. PBM emphasizes preoperative anemia management, minimally invasive surgical techniques, and judicious use of blood products based on individual patient needs.[71]

**Innovative Solutions**

1. **Advanced Blood Testing Technologies**: The advent of nucleic acid testing (NAT) and other advanced screening technologies has revolutionized blood testing, enhancing the detection of infectious agents and improving the safety of blood products. Rapid point-of-care testing for blood typing and cross-matching facilitates timely transfusion decisions, particularly in emergency settings.[72]
2. **Blood Conservation Strategies**: Innovative techniques such as intraoperative cell salvage, autologous blood transfusion, and pharmacologic agents for hemostasis optimization reduce reliance on allogeneic blood transfusions. These strategies minimize exposure to donor blood, lower transfusion-related risks, and improve patient outcomes.[73]
3. **Transfusion Alternatives and Adjuncts**: Emerging therapies such as hemoglobin-based oxygen carriers, artificial blood substitutes, and recombinant factors offer potential alternatives to traditional blood transfusions in specific clinical scenarios. These adjunctive therapies complement standard transfusion practices, providing tailored treatment options for patients with complex medical conditions.
4. **Personalized Transfusion Medicine**: Advances in genomics and immunology facilitate personalized transfusion approaches, enabling clinicians to tailor transfusion therapy based

on individual patient characteristics, including genetic blood group variants and immunological profiles. This precision medicine approach enhances transfusion safety and efficacy, minimizing adverse reactions and optimizing therapeutic outcomes.

## Conclusion

The optimization of transfusion practices represents a critical endeavor in modern healthcare aimed at enhancing patient outcomes through innovation, collaboration, and evidence-based strategies. Throughout various medical specialties, from critical care to surgery and obstetrics, transfusion therapy remains indispensable yet complex. It requires a delicate balance between meeting immediate clinical needs and minimizing potential risks associated with transfusions. Advances in technology, such as advanced blood testing and personalized medicine approaches, have significantly improved the safety and efficacy of transfusion practices. These innovations enable healthcare providers to make more informed decisions, tailor treatments to individual patient profiles, and reduce reliance on allogeneic blood products where feasible. Moreover, the integration of blood conservation strategies and the promotion of patient blood management initiatives are pivotal in optimizing resource utilization, reducing transfusion requirements, and improving patient outcomes. These approaches underscore the importance of a comprehensive, multidisciplinary approach to transfusion medicine, where collaboration among clinicians, transfusion specialists, laboratory personnel, and administrators is essential.

## References

1. Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal and perinatal morbidity and mortality associated with anemia in pregnancy. Obstetrics & Gynecology. 2019;134(6):1234-1244.
2. Shi H, Chen L, Wang Y, Sun M, Guo Y, Ma S, Wang X, Jiang H, Wang X, Lu J, Ge L. Severity of anemia during pregnancy and adverse maternal and fetal outcomes. JAMA network open. 2022;5(2):e2147046-.
3. Harrison RK, Lauhon SR, Colvin ZA, McIntosh JJ. Maternal anemia and severe maternal morbidity in a US cohort. American journal of obstetrics & gynecology MFM. 2021;3(5):100395.
4. Beckert RH, Baer RJ, Anderson JG, Jelliffe-Pawlowski LL, Rogers EE. Maternal anemia and pregnancy outcomes: a population-based study. Journal of Perinatology. 2019;39(7):911-919.
5. Daru J, Zamora J, Fernández-Félix BM, Vogel J, Oladapo OT, Morisaki N, Tunçalp Ö, Torloni MR, Mittal S, Jayaratne K, Lumbiganon P. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. The Lancet Global Health. 2018;6(5):e548-554.
6. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC, Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria, J Res Med Dent Sci, 2021, 9 (4):145-148
7. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138.

links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.

8. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
9. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-8. links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
10. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 ;6(2):10-3. http://irmhs.com/index.php/irmhs/article/view/111.
11. Georgieff MK. Iron deficiency in pregnancy. American journal of obstetrics and gynecology. 2020;223(4):516-524.
12. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
13. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57.
14. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-941.
15. Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M. Routine iron supplementation and screening for iron deficiency anemia in pregnancy: a systematic review for the US Preventive Services Task Force. Annals of internal medicine. 2015;162(8):566-576.
16. Siu AL, US Preventive Services Task Force*. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2015;163(7):529-536.
17. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9): 21-6.DOI: 10.22192/ijcrcps.2022.09.09.003
18. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna University Journal of Medicine and Health Sciences. 2022;2(2):91-97. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67.
19. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science. 2021;9(12):462-.links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-

Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf.

20. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022 Jun 21;5(2):113-121.
21. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163. links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf.
22. Liu CN, Yu FB, Xu YZ, Li JS, Guan ZH, Sun MN, Liu CA, He F, Chen DJ. Prevalence and risk factors of severe postpartum hemorrhage: a retrospective cohort study. BMC pregnancy and childbirth. 2021;21(1):332.
23. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
24. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3): 134-43.DOI: 10.22192/ijarbs.2023.10.03.016
25. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-43. links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf.
26. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
27. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206. links/5ea97df145851592d6a8acf2/Iron-Status-of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf.
28. Eze RI, Obeagu EI, Edet FN. Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. Madonna Uni J Med Health Sci. 2021;1(1):19-30.
29. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. J Pub Health Nutri. 2023; 6 (1). 2023; 137:26-35. links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf.
30. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2): 14-17.DOI: 10.22192/ijcrms.2023.09.02.003
31. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 14-21.DOI: 10.22192/ijcrcps.2023.10.08.002

32. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. An update on the use of massive transfusion protocols in obstetrics. American journal of obstetrics and gynecology. 2016;214(3):340-344.
33. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9): 1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
34. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. Int J Curr Res Biol Med. 2017;2(2): 13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
35. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
36. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(7):43-50.
37. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
38. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. Jama. 2016;316(19):2025-2035.
39. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4): 40-4.DOI: 10.22192/ijcrcps.2023.10.04.004
40. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. Int. J. Curr. Res. Med. Sci. 2023;9(5): 31-35.DOI: 10.22192/ijcrms.2023.09.05.005
41. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, Okafor CJ, Chukwurah EF, Chijioke UO, Amaechi CO. Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. Journal of Pharmaceutical Research International. 2021;33(30A):67-71.
42. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7): 25-28.DOI: 10.22192/ijcrms.2023.09.07.005
43. Obeagu EI, Bunu UO. Factors that influence unmet need for family planning. International Journal of Current Research in Biology and Medicine. 2023;8(1):23-27.
44. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. International Journal of Advanced Multidisciplinary Research. 2017;4(8): 1-9.DOI: 10.22192/ijamr.2017.04.08.001
45. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.

46. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9): 41-9.DOI: 10.22192/ijcrms.2018.04.09.006
47. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 22-6.DOI: 10.22192/ijcrcps.2023.10.08.003
48. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. Madonna University journal of Medicine and Health Sciences. 2022;2(1):134-48. https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40.
49. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. The American journal of clinical nutrition. 2016;103(2):495-504.
50. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
51. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. migration. 2023; 17:18.
52. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4. https://www.academia.edu/download/56538560/A_Review_on_Erythropietin_in_Pregnancy.pdf.
53. Ifeanyi OE. A review on pregnancy and haematology. Int. J. Curr. Res. Biol. Med. 2018;3(5): 26-8.DOI: 10.22192/ijcrbm.2018.03.05.006
54. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. International Journal of Current Research and Academic Review. 2015;3(5):376-383.
55. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2017;4(7):28-33.
56. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A. Evaluation of iron status and some haematological parameters of pregnant women in Enugu, South Eastern Nigeria. World Journal of Pharmaceutical and Medical Research. 2021;7(5):251-4.
57. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. IOSR Journal of Pharmacy and Biological Sciences. 2014;9(5):59-64.
58. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. Asian Research Journal of Gynaecology and Obstetrics. 2022;8(3):12-26.
59. Tandon R, Jain A, Malhotra P. Management of iron deficiency anemia in pregnancy in India. Indian Journal of Hematology and Blood Transfusion. 2018; 34:204-215.

60. Montoro M, Cucala M, Lanas Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa ÁP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. Frontiers in Medicine. 2022; 9:903739.
61. Kapur D, Nath Agarwal K, Kumari Agarwal D. Nutritional anemia and its control. The Indian Journal of Pediatrics. 2002; 69:607-616.
62. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. European Journal of Biomedical. 2023;10(9):272-275. links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf.
63. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
64. Hasan MM, Magalhaes RJ, Garnett SP, Fatima Y, Tariqujjaman M, Pervin S, Ahmed S, Mamun AA. Anaemia in women of reproductive age in low-and middle-income countries: progress towards the 2025 global nutrition target. Bulletin of the World Health Organization. 2022;100(3):196.
65. Paulman PM, Paulman A, Harrison JD, Nasir LS, Bryan SK, Collier DS. Signs and Symptoms in Family Medicine E-Book: A Literature-Based Approach. Elsevier Health Sciences; 2011.
66. Stoffel NU, von Siebenthal HK, Moretti D, Zimmermann MB. Oral iron supplementation in iron-deficient women: How much and how often? Molecular aspects of medicine. 2020; 75:100865.
67. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):39-48.
68. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-26.
69. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
70. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstetrics & Gynecology. 2005;106(6):1335-1340.
71. Ngwenya S. Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting. International journal of women's health. 2016:647-650.
72. Obeagu EI, Ubosi NI, Uzoma G. Maternal Hemorrhage and Blood Transfusions: Safeguarding Pregnancy Health. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):26-35.
73. Obeagu EI, Obeagu GU. The Vital Role of Blood Transfusions during Pregnancy: A Comprehensive Review. Asian Journal of Dental and Health Sciences. 2024;4(1):26-31.